Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$8.23 USD
+0.60 (7.86%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.22 -0.01 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VIR 8.23 +0.60(7.86%)
Will VIR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIR
What Makes Vir Biotechnology (VIR) a New Buy Stock
Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why
Other News for VIR
Vir Biotechnology Announces CFO Departure and Board Expansion
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares
Vir Biotechnology CEO sells 72,995 common shares